<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../figures/favicon.png" type="image/x-icon">
  <title>Asthma in Pregnancy</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="/style.css">
  <link rel="stylesheet" href="/notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="/index.html">
    <div class="home-navigation">
      M
    </div>
  </a>

  <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="/index.html">Home</a>
      </li>
      <li class="menu__item">
        <a class="menu__link" href="/about-temp2.html">About</a>
      </li>
      
     
      

      <!-- <li class="menu__item">
        <a class="menu__link" href="#0">Projects</a>
        <ul class="submenu">
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Surgery</a>
          </li>
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Pediatrics</a>
          </li>
        </ul>
      </li> -->
    </ul>
  </nav>
  
  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterðŸ’œ</p>
      <span><a href="/contribute.html">Contribute here</a> </span>
    </div>

    <h1>Asthma in Pregnancy</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
        <a id='top'></a>
    <article>
    <!-- <h2 class='title'>Outline</h2> -->
    <label class="trigger outline">
        <input type="checkbox" class="checkbox checkbox--red" /> Show/hide outline
        <div class="msg">
         <ol>
            <li><a href="#header-1">Introduction</a></li>
            <li><a href="#header-2">Pathophysiology</a></li>
            <li><a href="#header-3">Significance in Obstetrics</a></li>
            <li><a href="#header-4">Respiratory changes in pregnancy</a></li>
            <li><a href="#header-5">Asthma and Pregnancy</a></li>
            <li><a href="#header-6">Clinical presentation</a></li>
            <li><a href="#header-7">Investigations</a></li>
            <li><a href="#header-8">Classification of Asthma</a></li>
            <li><a href="#header-9">Differential diagnosis</a></li>
            <li><a href="#header-10">Management</a></li>
            <li><a href="#header-11">Conclusion</a></li>

         </ol>
        </div>
      </label>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
          <p>It is a common obstructive pulmonary disease </p>
          <p>Affects millions of people worldwide and complicates about 8% of pregnancies </p>
          <p>May be the most common potentially serious medical complication of pregnancy</p>
          <p>It is a chronic disease </p>
          <p>Can be life-threatening in severe or poorly controlled cases </p>
          <p>Episodic; symptom free periods and acute exacerbations </p>
          <p>Characterized by increased responsiveness of the tracheobronchial tree to multiple stimuli.</p>

          <h4><span class="special-text-4">Definitions </span></h4>
          <p><span class="special-text">Total lung capacity</span>: maximum volume of air present in the lungs at end of maximal inspiration </p>
          <p><span class="special-text">Functional residual capacity</span>: volume of air present at end of passive expiration </p>
          <p><span class="special-text">Tidal volume</span>: amount of air inhaled or exhaled normally at rest  </p>
          <p><span class="special-text">Forced vital capacity</span>: amount of air that can be expelled from the lungs after taking the deepest possible breath  </p>
          <p><span class="special-text">Peak expiratory flow rate (PEFR)</span>: lung function test that measures how fast a person can exhale </p>
          <p><span class="special-text">Forced expiratory volume in 1 second (FEV<sub>1</sub>)</span>: measures how much a person can exhale during a forced breath in the 1st second.</p>
        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Pathophysiology </a>
          </h2>
        </header>
        <div class='body'>
            <p>Characterized by chronic inflammation, swelling and narrowing of bronchial tubes resulting in difficulty in breathing  </p>
            <p>The bronchial narrowing may be partially or completely reversible with or without treatment </p>
            <p>Chronically inflamed bronchial tubes may become overly sensitive to and remain in a state of heightened sensitivity called bronchial hyperactivity.</p>
        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Significance in Obstetrics </a>
          </h2>
        </header>
        <div class='body'>
          <h4><span class="special-text-4">Potential risks from maternal asthma</span></h4>
          <p><span class="special-text-4b">Maternal complications</span></p>
          <ul>
            <li>Pre-eclampsia</li>
            <li>Hypertension</li>
            <li>Toxemia</li>
            <li>C-section placenta previa</li>
            <li>Hyperemesis gravidarum</li>
          </ul>

          <h4><span class="special-text-4">Risk factors for exacerbations of asthma during pregnancy</span></h4>
          <ul>
            <li>Non-adherence with controller therapy</li>
            <li>Viral infections</li>
            <li>Diaphragmatic elevation of up to 4 cm</li>
            <li>Increased prostaglandin F2Î± may promote bronchoconstriction</li>
            <li>Asthma triggers</li>
            <li>Gastroedophageal reflux</li>
            <li>Imcreased emotional stress</li>
            <li>Increased progesterone levels result in centrally mediated hyperventilation, manifested as â€˜dyspnea of pregnancyâ€™</li>
          </ul>

        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Respiratory changes in pregnancy </a>
          </h2>
        </header>
        <div class='body'>
          <p>Results in higher O<sub>2</sub>  and lower PCO<sub>2</sub> </p>
          <p>Diaphragm elevated by 4 cm </p>
          <p>Increased transverse diameter (2cm) and chest circumference (5-7cm) </p>
          <p>Decrease in </p>
          <ul>
            <li>Total lung capacity </li>
            <li>Functional residual capacity  </li>
          </ul>
          <p>Increased tidal volume; (amount of air inhaled or exhaled normally at rest); progesterone effect </p>
          <p>No clinically significant change in  </p>
          <ul>
            <li>Forced vital capacity (amount of air that can be expelled from the lungs after taking the deepest possible breath)</li>
            <li>Peak expiratory flow rate (PEFR)  </li>
            <li>Forced expiratory volume in 1 second (FEV<sub>1</sub>) </li>
          </ul>
          <p>Airway resistance is reduced due to the progesterone-mediated bronchial and tracheal smooth muscle relaxation.</p>
          <p>Hypersensitivity to CO<sub>2</sub> increases the respiratory rate by 15%.</p>
          <p>Alveolar ventilation is about 70% higher at the end of gestation.</p>
          <p>Fall in arterial and alveolar carbon dioxide tensions.</p>
          <p>The development of alkalosis is forestalled by compensatory decreases in serum bicarbonate.</p>
          <p>Oxygen consumption and carbon dioxide production are increased by 60%.</p>
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Asthma and Pregnancy</a>
          </h2>
        </header>
        <div class='body'>
          <h4><span class="special-text-4">Effects of pregnancy on asthma </span></h4>
          <ul>
            <li> Variable effect: rule of thirds; 1/3rd improved, 1/3rd became worse, 1/3rd remains the same  </li>
            <li> Worsening symptoms may be due to cessation of drugs because of fear of adverse effects  </li>
            <li> Improvement in symptoms may be due to progesterone effect; smooth muscle relaxation </li>
            <li> The higher the severity of asthma, the worse the exacerbation</li>
          </ul>
          <h4><span class="special-text-4">Effects of asthma on pregnancy </span></h4>
          <ul>
            <li>No consensus but mild asthma/good control less likely to have complications and vice versa </li>
            <li> Effects on mother: pre-eclampsia, respiratory failure, death  </li>
            <li>Effects on fetus: preterm birth, low birth weight, IUGR, increased perinatal morbidity and mortality,  </li>
            <li>Exacerbations in first trimester is associated with increased risk of congenital malformations </li>
            <li> Lower FEV<sub>1</sub> during pregnancy is associated with increased risk of prematurity and low birth weight</li>
          </ul>

        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Clinical presentation </a>
          </h2>
        </header>
        <div class='body'>
           <p>Same as in non-pregnant state </p>
           <p>Symptoms: include wheezing, shortness of breath, chest tightness, cough</p>
           <p> May be worse at nights </p>
           <p> Exposure to triggers may be identified; these may be allergens or irritants </p>
           <ul>
            <li>Allergens e.g. pollen, dustmites, molds, fish, peanuts, latex, infections, exercise </li>
            <li>Irritants e.g. respiratory infections, smoke, NSAIDS, petrol fumes, insecticides, exhaust from cars, generators</li>
           </ul>

           <h4><span class="special-text-4">Symptoms and signs </span></h4>
           <ul>
            <li>Shortness of breath </li>
            <li>Wheezing </li>
            <li>Chest tightness </li>
            <li>Use of accessory muscles </li>
            <li>Tachypnea </li>
            <li>Rhonchi</li>
           </ul>
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'> Investigations  </a>
          </h2>
        </header>
        <div class='body'>
           <p>Pulmonary function tests </p>
           <ul>
            <li>FEV<sub>1</sub> (forced expiratory volume in 1 second; maximal amount of air that can be forcefully exhaled in the first second of a forced exhalation; requires a spirometer)</li>
            <li>PEFR (maximal rate at which a person can exhale during a short maximal expiratory effort after a full inspiration) </li>
           </ul>

           <h4><span class="special-text-4">FEV<sub>1</sub> </span></h4>
           <p>Best measure of pulmonary function </p>
           <p>Is converted to a percentage of normal based on the patientâ€™s height, weight and race.  </p>
           <p>It is a marker of the degree of obstruction in asthma patients  </p>
           <h4><span class="special-text-4b"> Classification </span></h4>
           <ol>
            <li>Normal: FEV<sub>1</sub> greater 80% of predicted  </li>
            <li>Mild obstruction: FEV<sub>1</sub> 60% to 79% of predicted  </li>
            <li>Moderate obstruction: FEV<sub>1</sub> 40% to 59% of predicted  </li>
            <li>Severe obstruction: FEV<sub>1</sub> less than 40% of predicted  </li>
           </ol>
           <p> In asthma, the FEV<sub>1</sub> is usually decreased because of an increased airway resistance to expiratory flow.</p>

           <h4><span class="special-text-4">PEFR </span></h4>
           <p> Correlates well with FEV<sub>1</sub> </p>
           <p> Easily measured with peak flow meter </p>
           <p> To perform a peak flow: </p>
           <ul>
            <li>Stand up straight. </li>
            <li>Make sure the indicator is at the bottom of the meter. </li>
            <li>Take a deep breath, filling your lungs completely. </li>
            <li>Place the mouthpiece in your mouth; lightly bite with your teeth, and close your lips on it. </li>
            <li>Blast the air out as hard and as fast as possible in a single blow.  Repeat 3 times and record the highest value obtained </li>
            <li>Keep a chart </li>
           </ul>
           <p>The Peak Exploratory Flow Rate (PEFR) correlates with the FEV<sub>1</sub></p>
           <p>Measured reliably with inexpensive, disposable, portable peak flow meters</p>
           <p>Insight to course of asthma throughout the day</p>
           <p>Help detect early signs of deterioration</p>
           <p>Twice daily- upon awakening and after 12hr.</p>

        </div>
      </section>

      <section id='header-8'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'>Classification of Asthma  </a>
          </h2>
        </header>
        <div class='body'>
           <h4><span class="special-text-4b">National Asthma Education and prevention program (NAEPP classification) </span></h4>
           <p></p>
           <ol>
            <li>Mild intermittent </li>
            <li>Mild persistent </li>
            <li>Moderate persistent </li>
            <li>Severe persistent</li>
           </ol>

           <h4><span class="special-text-4">Mild intermittent Asthma </span></h4>
           <ul>
            <li>Attacks occur â‰¤ twice per week </li>
            <li>Nocturnal attacks â‰¤ twice per month </li>
            <li>Normal PEFR or FEV<sub>1</sub> (â‰¥ 80% predicted), variability < 20%</li>
           </ul>
           <h4><span class="special-text-4">Mild persistent </span></h4>
           <ul>
            <li>Attacks occur >twice a week but not every day  </li>
            <li>Nocturnal attacks > twice a month </li>
            <li>Attacks are sometimes severe enough to affect regular activities </li>
            <li>Normal PEFR or FEV<sub>1</sub> (>80%)</li>
           </ul>
           <h4><span class="special-text-4">Moderate persistent </span></h4>
           <ul>
            <li>Attacks occur daily </li>
            <li>Nocturnal attacks occur > twice a week </li>
            <li>PEFR OR FEV<sub>1</sub> >60% to <80% predicted; variability >30% </li>
            <li>Regular medications necessary to control symptoms</li>
           </ul>
           <h4><span class="special-text-4">Severe persistent </span></h4>
           <ul>
            <li>Attacks occur frequently; continuous daytime symptoms/frequent exacerbations </li>
            <li>Frequent nocturnal symptoms </li>
            <li>Symptoms limit daily activity </li>
            <li>PEFR or FEV<sub>1</sub> â‰¤60% predicted, variability >30% </li>
            <li>Regular oral corticosteroids necessary to control symptoms</li>
           </ul>

        </div>
      </section>

      <section id='header-9'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-9'> Differential diagnosis </a>
          </h2>
        </header>
        <div class='body'>
           <ul>
            <li>Acute respiratory distress in pregnancy </li>
            <li>Physiologic dyspnea of pregnancy </li>
            <li>Asthma </li>
            <li>Pneumonia </li>
            <li>Peripartum cardiomyopathy </li>
            <li>COPD </li>
            <li>Amniotic fluid embolism</li>
           </ul>
        </div>
      </section>

      <section id='header-10'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-10'>Management  </a>
          </h2>
        </header>
        <div class='body'>
          <h4><span class="special-text-4"></span></h4>
          <ul>
            <li>Maintaining adequate oxygenation of the fetus by preventing hypoxic episodes in mother </li>
            <li>Achieving minimal or no maternal symptoms at day or night </li>
            <li>Minimal or no exacerbations </li>
            <li>No limitation of activity </li>
            <li>Maintenance of normal or near normal pulmonary function </li>
            <li>Minimal or no adverse effects from medications</li>
          </ul>

          <h4><span class="special-text-4">Components of effective management </span></h4>
          <ul>
            <li>Objective assessment and monitoring </li>
            <li>Patient education </li>
            <li>Avoidance or control of asthma triggers </li>
            <li>Drug therapy</li>
          </ul>

          <h4><span class="special-text-4b">Objective measures for assessment and monitoring </span></h4>
          <ul>
            <li>Gold standard: FEV<sub>1</sub> following maximal inspiration </li>
            <li>Mean FEV<sub>1</sub> < 80% predicted is associated with increased preterm delivery < 37 and birth weight <2500g </li>
            <li>PEFR correlates well with FEV<sub>1</sub> and can be easily measured with peak flow meters </li>
            <li>Typical PEFR in pregnancy is 380-550 L/min </li>
            <li>Pregnant woman should determine her personal best and calculate her PEFR zones: green > 80%; yellow 50-80%; red < 50% </li>
          </ul>

          <h4><span class="special-text-4b">Patient education  </span></h4>
          <ul>
            <li>Importance of good control   </li>
            <li>Identification and avoidance of triggers </li>
            <li>Medical management </li>
            <li>Self-monitoring of PEFR </li>
          </ul>
          <h4><i>Educational topics for asthmatic pregnant women:</i></h4>
          <ul>
            <li>Stop smoking</li>
            <li>Use of inhaler devices</li>
            <li>Adherence to treatment</li>
            <li>Environmental control</li>
            <li>Self-treatment action plan</li>
          </ul>

          <h4><span class="special-text-4b">Avoidance or control of triggers </span></h4>
          <ul>
            <li>Common association between asthma and allergy; 75-85% asthma patients have positive skin test to common allergens e.g. animal dander, household mite, cockroach antigen</li>
          </ul>

          <h4><span class="special-text-4b">Drug therapy </span></h4>
          <ul>
            <li>Minimum drugs that control symptoms </li>
            <li>2 groups; rescue and maintenance </li>
          </ul>
          <h4>Rescue agents </h4>
          <ul>
            <li>Used to treat acute bronchospasm and provide symptomatic relief  </li>
            <li>Does not treat the underlying inflammation  </li>
            <li> E.g. beta-2 agonists, anti-cholinergics </li>
          </ul>
          <h4> Maintenance agents </h4>
          <ul>
            <li> Treat underlying inflammation </li>
            <li> E.g. steroids, leukotriene antagonists, cromolyn</li>
          </ul>

          <section id='heading-10-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-10-1'>General principle of drug therapy </a>
              </h3>
            </header>
            <div class='body'>
               <p>It is safer for a pregnant woman to take asthma medications during pregnancy than for her to experience asthma symptoms and exacerbations because inadequate asthma control is a greater risk to the fetus than asthma medication.</p>
               <p>Step therapy: increasing number and frequency of medication with increasing asthma severity </p>

               <h4><span class="special-text-4">Step 1: mild intermittent </span></h4>
               <h4><span class="special-text-4b">Clinical presentation </span></h4>
               <ul>
                <li>Intermittent symptoms </li>
                <li>Brief exacerbations </li>
                <li>Normal between exacerbations Night-time symptoms < 2/month  </li>
                <li>PEF or FEV<sub>1</sub> > 80% predicted Controller: No daily medications </li>
               </ul>
               <h4><span class="special-text-4b">Treatment </span></h4>
               <ul>
                <li>Quick relief: Inhaled beta 2 agonists e.g.  Salbutamol, Albuterol as needed (usually 2-4 puffs every 4-6 hours or as needed) </li>
                <li>Side effects: tremor, palpitations, tachycardia</li>
               </ul>

               <h4><span class="special-text-4">Step 2: Mild persistent </span></h4>
               <h4><span class="special-text-4b"> Clinical presentation </span></h4>
               <ul>
                <li>Symptoms >2x/week; night time symptoms > 2x/month; PEF/FEV<sub>1</sub> >80% predicted </li>
               </ul>
               <h4><span class="special-text-4b">Treatment </span></h4>
               <ul>
                <li>Low dose inhaled corticosteroids (theophylline or leukotriene receptor antagonist (LTRA) as an alternative)</li>
               </ul>

               <h4><span class="special-text-4">Step 3: Moderate Persistent Asthma  </span></h4>
               <h4><span class="special-text-4b">Clinical presentation </span></h4>
               <ul>
                <li>Attacks occur daily </li>
                <li>Nocturnal attacks occur > twice a week </li>
                <li>PEFR OR FEV<sub>1</sub> >60% to <80% predicted; variability >30%  </li>
               </ul>
               <h4><span class="special-text-4b">Treatment: </span></h4>
               <ul>
                <li>Controller: Medium dose inhaled corticosteroids  </li>
                <li>Alternative: low dose inhaled corticosteroids +long acting beta agonist (LABA); leukotriene receptor antagonist (LTRA), Theophylline </li>
                <li>Quick relief: inhaled B<sub>2</sub> agonist</li>
               </ul>

               <h4><span class="special-text-4">Step 4: Moderate Persistent </span></h4>
               <ul>
                <li>Medium dose inhaled corticosteroids + LABA  </li>
                <li>Alternative: medium dose inhaled  corticosteroids + LTRA </li>
                <li>Theophylline</li>
               </ul>

               <h4><span class="special-text-4">Step 5: Severe Persistent  </span></h4>
               <ul>
                <li>Attacks occur frequently; continuous daytime symptoms/frequent exacerbations </li>
                <li>Frequent nocturnal symptoms </li>
                <li>Symptoms limit daily activity </li>
                <li>PEFR or FEV<sub>1</sub> â‰¤60% predicted, variability >30% </li>
                <li>If additional medication is required after carefully assessing the patient and her adherence with using Step 3 medication, high dose inhaled corticosteroids and Long Acting Beta Agonist</li>
               </ul>

               <h4><span class="special-text-4">Step 6: Severe persistent </span></h4>
               <ul>
                <li>High dose inhaled corticosteroid + LABA + systemic corticosteroid e.g. oral prednisolone</li>
               </ul>





            </div>
          </section>

          <section id='heading-10-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-10-2'>Management of Acute Exacerbations </a>
              </h3>
            </header>
            <div class='body'>
               <p>Assess promptly: Use of accessory muscles of respiration suggests severe exacerbation </p>
               <p>Commence oxygen to keep PaO<sub>2</sub>>95%. </p>
               <p>Give supplemental oxygen if < 95% </p>
               <p>IVF rehydration if necessary </p>
               <p>Commence bronchodilators e.g. beta-2 agonists or nebulized albuterol </p>
               <p>Systemic steroids: convert to oral after improvement occurs and taper off </p>

               <h4><span class="special-text-4"> Investigations</span></h4>
               <ul>
                <li>PEFR, arterial blood gases </li>
                <li>Pulse oximeter</li>
                <ul>
                  <li>Assess oxygenation by measuring the arterial oxygen saturation of hemoglobin</li>
                  <li>The proper use of a pulse oximeter can ensure earlier detection of hypoxia</li>
                  <li>A normal SPO<sub>2</sub> range is 95% to 100%</li>
                  <li>SPO<sub>2</sub> is one patient-assessment tool and should be interpreted along with other patient data including vital signs, cardiac rhythm, and breath sounds.</li>
                </ul>
               </ul>

               <h4><span class="special-text-4b">In pregnant women, confirm control by </span></h4>
               <ul>
                <li>Spirometry </li>
                <li>Peak flow meter twice daily</li>
               </ul>

               <h4><span class="special-text-4b">Fetal Surveillance during Pregnancy </span></h4>
               <ul>
                <li>Early USS to confirm cyesis and date pregnancy</li>
                <li>Serial USS from 32 weeks in poorly controlled asthma and women with moderate-severe asthma </li>
               </ul>


            </div>
          </section>

          <section id='heading-10-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-10-3'>Labor and delivery </a>
              </h3>
            </header>
            <div class='body'>
               <p>Asthma attacks during labor are very rare because of high levels of cortisone and adrenaline. Reliever inhalers can be used effectively</p>
               <p>Precautions against latex allergy are necessary if present</p>
               <p>Local anesthetic is preferred.</p>
               <p>Exacerbations of asthma during labor are rare.  Continue Asthma medications.  </p>
               <p>Prostaglandin E<sub>2</sub> and oxytocin can be safely used in asthmatics.   Ergot derivatives can cause bronchospasm so avoid  </p>
               <p>Adequate analgesia to prevent bronchospasm </p>
               <p>Regional anesthesia is also preferred for surgery (decreases oxygen consumption and minute ventilation; avoids risk of chest infection and atelectasis) </p>
            </div>
          </section>

          <section id='heading-10-4'>
            <header>
              <h3>
                <a aria-hidden href='#heading-10-4'>Asthma and lactation</a>
              </h3>
            </header>
            <div class='body'>
               <p>There is no effect of lactation on maternal asthma</p>
               <p>Prednisone, theophylline, antihistamines, ICS, SABAs, LABAs and cromolyn are not contraindicated.</p>
               <p>Theophylline may cause neonatal irritability, feeding difficulties.</p>
            </div>
          </section>

          <section id='heading-10-5'>
            <header>
              <h3>
                <a aria-hidden href='#heading-10-5'>Status asthmaticus </a>
              </h3>
            </header>
            <div class='body'>
               <p> Obstetric emergency </p>
               <p> Multidisciplinary management </p>
               <p> ICU care: intubation, mechanical ventilation</p>
            </div>
          </section>

          <section id='heading-10-6'>
            <header>
              <h3>
                <a aria-hidden href='#heading-10-6'>Preconception </a>
              </h3>
            </header>
            <div class='body'>
               <p> Optimize asthma management </p>
               <p> Avoid drugs whose safety during pregnancy is not established </p>
               <p> Patient education </p>
            </div>
          </section>



        </div>
      </section>

      <section id='header-11'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-11'> Conclusion  </a>
          </h2>
        </header>
        <div class='body'>
           <p>Asthma in pregnancy is an increasingly common problem </p>
           <p>Excellent maternal and perinatal outcome can be obtained particularly for mild-moderate cases </p>
           <p>Severe cases may be associated with increased maternal and perinatal morbidity and mortality </p>
        </div>
      </section>


      </section>

      <div class="contact">
        <hr style="margin: 3rem 0;">

        <p>Send us a <a href="mailto:obgyn.materia@gmail.com"><span class="special-text-2">mail</span></a> at 
         <br> obgyn.materia@gmail.com.</p>
        <p>Or send your comments, corrections, explanations/clarifications and requests/suggestions to our 
         <br> <a href="" class="special-text-2" style="text-decoration: none;">WhatsApp group</a>.</p>
      </div>
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p>obgyn.materia</p>
          
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="/main.js"></script>
</body>
</html>
 
